Formulation, optimization and evaluation of curcumin-β-cyclodextrin-loaded sponge for effective drug delivery in thermal burns chemotherapy

Figures & data

Table 1. Loading efficacy of different formulations.

Batch	Beta-cyclodextrin (mg)	Curcumin (mg)	Loading of curcumin in per mg of complex (µg)
1	80	10	2.53
2	80	20	8.78
3	80	30	15.41
4	80	40	22.41
5	80	50	22.53

Bold values represent the optimized formulation, which were used for further studies.

Figure 1. IR Spectrum of curcumin (a) and curcumin-β-cyclodextrin complex (b).

Table 2. Optimization of gelatin, formaldehyde and curcumin-β-cyclodextrin complex concentration.

Formulation	Speed (rpm)	Gelatin solution (% w/v)	Formaldehyde (% v/v)	Curcumin-β- cyclodextrin (% w/v)	Foam Stability	Pore size (μm)	Foam volume after 1 h (ml)
F1	3000	4	–	–	Stable	350–400	–
	4000	4	–	–	Stable	250–300	–
	5000	4	–	–	Stable	200–250	–
	6000	4	–	–	Stable	200–240	–
F2	3000	5	–	–	Stable	70–220	–
	4000	5	–	–	Stable	80–210	–
	5000	5	–	–	Stable	80–140	–
	6000	5	–	–	Stable	80–140	–
F3	5000	5	0.1	–	Unstable	80–140	20–18
F4	5000	5	0.2	–	Unstable	92–160	20–17.5
F5	5000	5	0.3	–	Stable	80–120	20–19.5
F6	5000	5	0.4	–	Unstable	85–150	20–18
F7	5000	5	0.5	–	Unstable	90–180	20–17
F8	5000	5	0.3	0.5	Stable	60–120	19.8–19.5
F9	5000	5	0.3	1	Stable	62–140	19.4–19.2
F10	5000	5	0.3	1.5	Stable	75–150	19.2–19
F11	5000	5	0.3	2	Stable	80–170	19–18.5
F12	5000	5	0.3	2.5	Unstable	80–210	18.9–17.5

Bold values represent the optimized formulation, which were used for further studies.

Figure 2. A photomicrograph of 5% gelatin stable foam (a) and curcumin-β-cyclodextrin-loaded gelatin sponge (b) at 100×s.

Figure 3. In vitro release of drug from sponge containing formaldehyde and without containing formaldehyde.

Figure 4. Histopathology of (a) plain cyclodextrin-treated group, (b) gelatin gel-treated group, (c) plain curcumin-treated group, (d) silver sulfadiazine-treated group and (e) curcumin-β-cyclodextrin sponge-treated group.

Figure 5. (a) Plain cyclodextrin-treated group, (b) gelatin gel-treated group, (c) plain curcumin-treated group, (d) silver sulfadiazine-treated group and (e) curcumin-β-cyclodextrin-loaded sponge treated group.

Figure 6. Changes in area of wound contraction during the progress of wound healing.